Oxford Immunotec Reports Fourth Quarter and Full Year 2017 Financial Results

Oxford Immunotec Global (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced fourth quarter and full year 2017 financial results.

As quoted in the press release:

“While the year contained many ups and downs, in aggregate I am pleased with the substantial progress made throughout the Company in 2017” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “2017 highlights included stronger-than-expected performance in Asia, a marked acceleration in Europe & ROW revenue growth, outperformance of our clinical tick-borne disease business, and the successful culmination of several strategically important multi-year initiatives on intellectual property, royalties and reimbursement.”

Click here to read the full press release.